Regeneron Pharmaceuticals Inc (REGN) Earns “Buy” Rating from Credit Suisse Group AG

Credit Suisse Group AG reaffirmed their buy rating on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in a research report report published on Monday morning, StockTargetPrices.com reports. Credit Suisse Group AG currently has a $485.00 price target on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. Barclays PLC increased their price target on Regeneron Pharmaceuticals from $375.00 to $400.00 and gave the stock an equal weight rating in a research note on Monday, May 8th. Cowen and Company reiterated a hold rating and set a $380.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday. Leerink Swann set a $448.00 price target on Regeneron Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, February 11th. Vetr downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating and set a $408.86 price target for the company. in a research note on Monday, May 8th. Finally, Canaccord Genuity reiterated a hold rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, February 10th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $432.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.88% during midday trading on Monday, hitting $448.71. The stock had a trading volume of 619,273 shares. The company has a 50-day moving average price of $397.84 and a 200-day moving average price of $380.88. The stock has a market cap of $47.37 billion, a P/E ratio of 54.32 and a beta of 1.44. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $462.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.42. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.57 EPS. Equities analysts expect that Regeneron Pharmaceuticals will post $12.67 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/05/19/regeneron-pharmaceuticals-inc-regn-earns-buy-rating-from-credit-suisse-group-ag.html.

In other news, Director Michael S. Brown sold 1,000 shares of the company’s stock in a transaction dated Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total value of $400,000.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $400,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The disclosure for this sale can be found here. Corporate insiders own 10.40% of the company’s stock.

Large investors have recently bought and sold shares of the company. Jennison Associates LLC increased its stake in Regeneron Pharmaceuticals by 4.5% in the third quarter. Jennison Associates LLC now owns 2,122,148 shares of the biopharmaceutical company’s stock worth $853,146,000 after buying an additional 91,223 shares in the last quarter. Grandfield & Dodd LLC increased its stake in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 17 shares in the last quarter. Opus Point Partners Management LLC increased its stake in Regeneron Pharmaceuticals by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 7,684 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 172 shares in the last quarter. Highbridge Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $323,000. Finally, Sustainable Growth Advisers LP increased its stake in Regeneron Pharmaceuticals by 6.4% in the third quarter. Sustainable Growth Advisers LP now owns 442,437 shares of the biopharmaceutical company’s stock worth $177,868,000 after buying an additional 26,613 shares in the last quarter. Institutional investors own 68.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Stock Target Prices

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply